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Rationale, Aims and Objectives Evidence‐based guidelines constitute a foundation for
medical decision making. It is often unclear whether recommendations in general guidelines also
apply to older people. This study aimed to develop a methodology to increase the focus on older
people in the development of guidelines.
Methods The methodology distinguishes 4 groups of older people: (1) relatively healthy older
people; (2) older people with 1 additional specific (interfering) comorbid condition; (3) older peo-
ple with multimorbidity; and (4) vulnerable older people.
Results The level of focus on older people required may be determined by the prevalence of
the disease or condition, level of suffering, social relevance, and the expectation that a guideline
may improve the quality of care.
A specialist in geriatric medicine may be involved in the guideline process via participation, pro-
vision of feedback on drafts, or involvement in the analysis of problem areas. Regarding the
patient perspective, it is advised to involve organisations for older people or informal carers in
the inventory of problem areas, and additionally to perform literature research of patient values
on the subject. If the guideline focuses on older people, then the relative importance of the var-
ious outcome measures for this target group needs to be explicitly stated.
Search strategies for all the 4 groups are suggested. For clinical studies that focus on the treat-
ment of diseases that frequently occur in older people, a check should be made regarding
whether these studies produce the required evidence. This can be achieved by verifying if there
is sufficient representation of older people in the studies and determining if there is a separate
reporting of results applying to this age group.1 | INTRODUCTION
In current medical practice, evidence‐based medicine featuring evi-
dence‐based guidelines constitutes an important foundation for medi-
cal decision making. Evidence‐based treatment of older people and
their care is a constant challenge given that this category is signifi-
cantly underrepresented in scientific research. A key cause of this
underrepresentation is that both biomedical research and health care
are largely organised around a single disease or disorder.1 The older
population—particularly frail older people—often suffer from
multiorgan problems that require a more integrated approach.2 One
of the consequences of this underrepresentation of the olderwileyonlinelibrarpopulation in biomedical research is that their frequently used medica-
tions have not been evaluated.3 When older people do participate in
trials, they are, for the most part, relatively healthy, have relatively little
or no comorbidity, and are often not frail.4
It has already become apparent in healthy older people that out-
comes of treatment may differ from those of young adults with the
same disease. It is to be expected for frail older people, or those with
multimorbidity, that there will be further divergence.1,5 In addition,
older people are often interested in other outcome measures, such as
remaining independent, quality of life, and the prevention of serious
side effects. A shorter life expectancy also plays a role in the consider-
ations, whilst shared decision making on whether or not to treat canJ Eval Clin Pract. 2018;24:254–257.y.com/journal/jep
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cally heterogeneous group of individuals to whom the results of clini-
cal‐scientific research into young adults cannot automatically be applied.
Currently, little attention has been paid to this (clinically heteroge-
neous) group of aged persons in guidelines and certainly not systemati-
cally, ie, in all stages of the development process of a guideline. One of
the consequences is that it is often not clear whether the guideline recom-
mendations do apply to older people.We aimed to develop amethodology
to increase the focus on older people in the development of guidelines.
This methodology is intended both for general guidelines and for guide-
lines that are specifically aimed at older people as a target group, and it
may be used by a guideline working groupwithout specialists in aged care.2 | METHODS
A core group consisting of a specialist in internal medicine and geriatrics
and 2 guideline methodologists wrote an initial draft text in 2014. This
draft text was complementary to an existing Dutch baseline guideline
methodology that already takes into account all basic steps for guideline
development, including the finalization stage. The document was submit-
ted to a working group of subject matter specialists and a guideline meth-
odologist for comments in several face to face meetings. In 2015, the
improved textwas submitted to a sounding board groupof subjectmatter
experts in the field of geriatric medicine, other diagnostic medical special-
ities or surgical specialities, and/or experts in the field of guideline devel-
opment. The suggestions and comments from the members of the
sounding board group were processed by the core group, after which
the revised versionwas submitted to theworking group for final approval.
Both core group, working group and sounding board group members
were selected based on their personal interest and expertise and had no
conflict of interest. Information about their background is supplied in
the supplement as well as in the online version.7 This version is
commented and authorised by the Quality Council (Raad Kwaliteit) of
de Dutch Medical Specialists, which sets quality standards for specialist
care. The present version is the result of this.
Examples were searched for in literature. The framework for crafting
clinical practice guidelines that are relevant to the care and management
of people with multimorbidity of Uhlig was used as a useful example for
the topics that had to be taken into account.8 Two stages of guideline
development were distinguished: the preparation stage and the develop-
ment stage. The preparation stage starts from the moment the develop-
ment of a guideline (de novo or an update) is considered. This includes
the choice of a subject, establishing which organisations should be
involved and lasts up to including the assembly of a working group. The
development stage starts with a comprehensive analysis of problem
areas, where a variety of stakeholders are heard. The development stage
ends when the working group has a draft guideline ready.3 | RESULTS
As treatment may differ depending on the health state of the aged per-
son, the methodology distinguishes 4 groups of older people, ie, per-
sons aged 65 and older. It is noted that category 4 partly overlaps
with categories 2 and 3:1. Relatively healthy older people;
2. Older people with 1 additional specific (interfering) comorbid con-
dition (disease, disorder). Interfering comorbidity refers to
coexisting conditions that impact upon the disease or disorder,
which is the subject of the guideline, namely, via “drug‐condition,
drug‐drug, and food‐drug interactions.”9 An example of interfer-
ing comorbidity is osteoporosis in older people with Chronic
Obstructive Pulmonary Disease (COPD).10 Medication with corti-
costeroids in connection with COPD negatively impacts bone
density and increases the risk of fractures.
3. Older people with multimorbidity (several coexisting chronic condi-
tions), where it does not concern a single, specific comorbid condition;
4. Frail older people. Vulnerability in older people is understood to
mean “the decrease of reserves and capacity through an accumu-
lation of deficiencies in several domains.”11 Frail older people
have an increased risk of negative health outcomes, such as falls,
delirium, or functional limitations, nonspecific symptoms such as
extreme fatigue or unexplained weight loss, frequently occurring
infections,2 postoperative complications, and mortality.123.1 | Preparation stage
3.1.1 | Subject and objective
The extent to which a specific focus on older people is required or
desirable within a guideline may be determined by applying the criteria,
as established by the Dutch Management Council for the Quality of
Care for the choice of a subject, to the target group of older people.13
These criteria are
• the prevalence of the disease or condition;
• the level of suffering;
• the social relevance; and
• the expectation that a guideline might improve the quality of care.
The decision to focus on a specific group of older people as defined
above depends on whether or not prevalent interfering comorbidity or
multimorbidity occurs in the target population of the guideline. For frail
older people, what will mainly be important is whether prognosis, care
organisation, or outcomemeasures justify attention for this specific target
group. The lack of scientific literature is, in itself, no reason not to pay
attention to one of the groups of older peoplementioned in the guideline.
So as to verify whether one of the groups of older people requires
more or less focus than another, a “quick search” of the literature may
be performed where older‐specific evidence in the form of systematic
reviews of landmark studies may be examined. It is also possible to
look at the availability of adjacent guidelines (that are currently being
developed), or ask for the expertise of subject matter specialists, in
particular that of a specialist in geriatric medicine. It is recommended
to state the decision to focus or not specifically on older people and
its rationale, in the introduction to the guideline, where other consider-
ations for the demarcation of the subject of the guideline are usually
mentioned as well. Also, the target group it involves (older people,
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people with multimorbidity or frail older people) and the starting ques-
tions that take this into account have to be made explicit.3.1.2 | Considerations for participation by a specialist in
aged care and organisations for older people in guideline
working groups
The composition of a working group for a guideline is initially deter-
mined by the subject. On the basis of the subject, the professional
groups primarily involved are approached by the initiator. When the
decision has been made to focus on older people, then this does not
necessarily imply that a specialist in geriatric medicine should partici-
pate in the working group. When most key questions on older pertain
to relatively healthy older people or older people with an interfering
comorbid condition that is (medically) treated, deployment may be lim-
ited to the provision of feedback within the framework of peer review.
In case of an interfering comorbid condition, it is also possible to con-
sider a medical specialist in the field of this specific comorbid condi-
tion. When most key questions on older people pertain to those with
multimorbidity, a choice between participation during the develop-
ment stage and providing feedback during the development stage
depends on the nature of the multimorbidity. When most key ques-
tions on older people pertain to frail older people, then participation
or the provision of feedback during the development stage by a spe-
cialist in older medicine is an obvious choice.3.2 | Development stage
3.2.1 | Inventory and analysis of problem areas
The beliefs, values, or preferences of older patients are of importance
for the preparation of the appropriate recommendations, in particular,
during the weighing of the pros and cons of treatment options.
Involvement of patient organisations for older people and organisa-
tions of informal carers within problem areas is therefore desirable.
Additionally, a literature research is recommended, preferably in
MEDLINE and the Cochrane Library. “Patient preferences,” “patient
satisfaction,” “patient experiences,” “patient participation,” “physician‐
patient relations,” and “shared decision making” may be used as (con-
trolled) keywords, in combination with the subject, and possibly limited
to systematic reviews and/or older[tiab] or AGED[Mesh].3.2.2 | Starting questions and outcome measures
Next to outcome measures such as mortality and morbidity, it is desir-
able to consider outcome measures such as quality of life,
hospitalisation, cognitive functioning, functional status, or treatment
burden in relation to older people. In addition, the required follow‐up
duration regarding the outcome measures should be considered
because this may be of importance in connection with the prognosis
(think of the time to benefit). It is recommended to determine the rel-
ative importance of the outcome measures for this target group. The
guideline development group should explicitly state which outcome
measures are crucial and important.3.2.3 | Systematic search for evidence
For all the search strategies listed below, the search results may be
narrowed down in a later stage to articles with a high average age, or
studies in which meta‐analyses (of individual patient data), subgroup
analyses, or results of meta‐regression are reported in relation to treat-
ment effect and interactions between treatment effect and comorbid-
ity and/or age categories of older people.
For older people of category 1: As a general rule, the same search
strategy will suffice as for younger adults.
For older people of category 2: For this category of older people,
keywords for the relevant comorbid condition need to be included in
the search query.
For older people of category 3: For this category of older people,
the following keywords are recommended (in PubMed)14:
Chronic disease [MeSH Major Topic] OR Comorbidity [MeSH
Major Topic] OR “Multiple chronic conditions” OR “Multiple
chronic illnesses” OR “Multiple chronic diseases” OR “Multiple
morbidity” OR “Multiple comorbidity” OR “Chronic condition”
OR “Chronic illness” OR “Multiple conditions” OR “Multiple
illnesses” OR “Multiple diseases” OR “Multimorbidity” OR
“Multimorbidity” OR “Multimorbidity” OR “Comorbid disease”)
AND Aged: 65+ years.
For older people of category 4: For this category of older people,
the following keywords are recommended (in PubMed)15:
“Frail Older”[Mesh] OR frail*[tiab] OR “short physical performance
battery”[tiab] OR “Sarcopenia”[Mesh]).
With respect to guidelines limited to the geriatric population, the
search strategy of the geriatrics search filter is recommended.16
For studies on interventions, with a view to internal validity and the
applicability of studies with regard to various categories of older people,
combining well‐performed (systematic reviews of) Randomized Con-
trolled Trial (RCTs) and observational studies, preferably prospective
cohort research, may have added value. This depends on the importance
of the key question as established by the working group in the prepara-
tion stage. For studies of diagnostic accuracy, it is preferable to focus on
systematic reviews on diagnostic test accuracy (assuming RCTs of diag-
nostic strategies are generally absent), or on studies with subgroup anal-
yses and “age factors.”
3.2.4 | Summarising study characteristics
For clinical studies that focus on the treatment of diseases that fre-
quently occur in older people, a check should be made regarding
whether these studies produce the required evidence for elderly peo-
ple by verifying the following:
• whether older people are well represented in the studies,
• whether it concerns a representative population of older people, and
• whether the results (effectiveness and toxicity) of interventions in
older people are specified separately.
3.2.5 | Determining the quality of evidence for every out-
come measure as well as the overall quality of evidence
The overall quality of evidence may vary for the different categories of
older people because
VAN MUNSTER ET AL. 257• various outcome measures may be used;
• the relative importance of an outcome measure may differ; and
• the quality of evidence may differ for each outcome measure,
among others, due to indirect evidence.
In the event of a lack of subgroup analyses or results of meta‐regres-
sions that give information on the effects of (diagnostic or therapeutic)
interventions in older people, it may be checked whether effects for a
specific outcome measure in studies that present overall results vary
according to the average age of the study population or the percentage
of patients with, for example, the relevant comorbidity in each study.
3.2.6 | Formulating and implementing recommendations
When examining the balance of desired and undesired effects for (the
various categories of) older people, consider the following:




• physical, mental, and emotional capacity of a patient;
• prognosis (remaining life expectancy, functional status, years spent
with limitations, quality of life); and
• the values and preferences of patients.
When implementing recommendations for older people, consider
what specific impeding factors (at the level of individual care providers,
at the level of the organisation, and at the level of the system) exist for
their application, and in particular, how they may be addressed.
Although (national) approval and implementation is the most impor-
tant but also hardest part, the finalization stage is not described in this
methodology, because this stage is mostly determined by local organisa-
tion of care. By including Dutch experts in the development of the meth-
odology, we hope that we have created some support to facilitate the
implementation. Before implementing this methodology in other coun-
tries, it might be necessary to adjust the methods to the national process.
In general, it is important to involve the geriatric or internal medicine
society to review the guideline before finalization if they were not
involved in the development. Creating public support by involving
patient as well‐regulatory organisations as well as media might help in
the final implementation of the recommendations for older people,4 | CONCLUSION
The epidemiologic approaches described above may help guideline
developers as a type of checklist that should systematically be consid-
ered during guideline development. Although, implementation of such
a methodology is quite a challenge, we feel that given the risk of worse
outcomes in a huge group of frail patients, researchers, guideline
developers, and funding institutions should give first priority to the
development of guidelines more appropriate for use in frail older per-
sons with multimorbity.ACKNOWLEDGEMENTS
This methodology originated at the initiative of the Dutch Association
of Internal Medicine (Dutch abbreviation: NIV) and the Dutch Geriat-
rics Society (Dutch abbreviation: NVKG). Special thanks to the working
group: Ir. T.A. van Barneveld, G.S. Spronk, and A.Y. Steutel.
REFERENCES
1. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the
recruitment of older patients with cancer onto clinical trials. J Clin
Oncol. 2005;23(13):3112‐3124.
2. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly
people. Lancet. 2013;381(9868):752‐762.
3. Watts G. Why the exclusion of older people from clinical research must
stop. BMJ (Online). 2012;344(7858):
4. McMurdo MET, Roberts H, Parker S, et al. Improving recruitment of older
people to research through good practice. Age Ageing. 2011;40(6):659‐665.
5. van de Glind EM, Rhodius‐Meester HF, Reitsma JB, Hooft L, van
Munster BC. Reviews of individual patient data (IPD) are useful for geri-
atrics: an overview of available IPD reviews. J Am Geriatr Soc.
2014;62(6):1133‐1138.
6. Scott IA, Guyatt GH. Cautionary tales in the interpretation of clinical
studies involving older persons. Arch Intern Med. 2010;170(7):587‐595.
7. https://internisten.nl/sites/internisten.nl/files/Addendum%20for%
20the%20creation%20of%20senior‐proof%20guidelines.pdf
8. Uhlig K, Leff B, Kent D, et al. A framework for crafting clinical practice
guidelines that are relevant to the care and management of people with
multimorbidity. J Gen Intern Med. 2014;29(4):670‐679.
9. Boyd CM, Fortin M. Future of multimorbidity research: how should
understanding of multimorbidity inform health system design? Public
Health Rev. 2011;33(2):451‐474.
10. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. The Lan-
cet. 2010;376(9743):803‐813.
11. Lutomski JE, Baars MA, Boter H, et al. Frailty, disability and multi‐mor-
bidity: the relationship with quality of life and healthcare costs in
elderly people. Ned Tijdschr Geneeskd. 2014;158:A7297.
12. Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of
frailty in older cancer patients: a systematic review. Ann Oncol.
2015;26(6):1091‐1101.
13. Care DMCftQo. Guideline for Guidelines 2012.
14. Guiding principles for the care of older adults with multimorbidity: an
approach for c. Guiding principles for the care of older adults with
multimorbidity: an approach for clinicians: American Geriatrics Society
expert panel on the Care of Older Adults with multimorbidity. J Am
Geriatr Soc. 2012;60(10):E1‐E25.
15. Bibas L, Levi M, Bendayan M, Mullie L, Forman DE, Afilalo J. Therapeu-
tic interventions for frail elderly patients: part I: published randomized
trials. Prog Cardiovasc Dis. 2014;57(2):134‐143.
16. van de Glind EM, van Munster BC, Spijker R, Scholten RJ, Hooft L.
Search filters to identify geriatric medicine in Medline. J Am Med Inform
Assoc. 2012;19(3):468‐472.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the
supporting information tab for this article.
How to cite this article: van Munster BC, Portielje JEA, Maier
AB, Arends AJ, de Beer JJA. Methodology for senior‐proof
guidelines: A practice example from the Netherlands. J Eval Clin
Pract. 2018;24:254–257. https://doi.org/10.1111/jep.12738
